

KAŻMIERCZAK, Martyna, PARYS, Jakub, MIKOSIŃSKA, Agnieszka, KALUZIAK, Patrycja, JAJCZAK, Marta, MOSSAKOWSKI, Maciej, WITEK, Aleksandra, LITWIN, Mateusz and JESIONEK, Stanisław. Comprehensive Management of Polycystic Ovary Syndrome: The Role of Metformin in Addressing Metabolic and Endocrine Dysregulation. Journal of Education, Health and Sport. 2025;77:57421. eISSN 2391-8306.
<https://doi.org/10.12775/JEHS.2025.77.57421>
<https://apcz.umk.pl/JEHS/article/view/57421>

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).

Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu). © The Authors 2025;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 30.11.2024. Revised: 05.01.2025. Accepted: 05.01.2025. Published: 07.01.2025.

Comprehensive Management of Polycystic Ovary Syndrome: The Role of Metformin in Addressing Metabolic and Endocrine Dysregulation

Martyna Kaźmierczak,

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

<https://orcid.org/0009-0007-7798-0069>

Jakub Parys,

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

<https://orcid.org/0009-0009-1955-7865>

Agnieszka Mikosińska,

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

<https://orcid.org/0009-0003-0891-9089>

Patrycja Kaluziak,

Charles Jonscher Medical Center,

ul. Milionowa 14, 93-113 Łódź, Poland

<https://orcid.org/0009-0008-0976-1523>

Marta Jajczak,

University Clinical Hospital No.2 of Medical University of Lodz,

ul. Żeromskiego 113, 90-549 Łódź, Poland

<https://orcid.org/0009-0009-6000-7769>

Maciej Mossakowski,

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

<https://orcid.org/0009-0008-0423-2083>

Aleksandra Witek,

Central Clinical Hospital of Medical University of Lodz,

ul. Pomorska 251, 92-213 Łódź, Poland

<https://orcid.org/0009-0002-1214-2199>

Mateusz Litwin,

University Clinical Hospital No.2 of Medical University of Lodz,

ul. Żeromskiego 113, 90-549 Łódź, Poland

<https://orcid.org/0009-0006-5131-1863>

Stanisław Jesionek,

Pabianice Medical Center Sp. o.o.,

ul. Jana Pawła II 68, 95-200 Pabianice, Poland

<https://orcid.org/0009-0004-6026-702X>

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine and metabolic disorder that affects women of reproductive age, characterized by hormonal imbalances, insulin resistance, and a range of clinical manifestations, including infertility and metabolic disturbances. Effective management of PCOS remains a challenge due to its multifaceted nature, necessitating a comprehensive understanding of therapeutic options.

Aim of the Study: This paper aims to explore the role of various treatment modalities for PCOS, with a particular emphasis on the use of metformin, an antidiabetic medication increasingly recognized for its benefits in managing insulin resistance and other associated conditions in PCOS patients.

Conclusion: The findings highlight metformin's three primary mechanisms of action: enhancing insulin sensitivity, inhibiting hepatic gluconeogenesis, and influencing lipid metabolism. Metformin is effective in improving metabolic parameters and restoring ovulatory function in women with PCOS. While it is a cornerstone of therapy, the management of PCOS

requires a tailored approach that considers individual clinical symptoms and phenotypes. Additional therapeutic strategies, including non-pharmacological measures and other pharmacological agents, play a vital role in a comprehensive treatment plan for PCOS.

Key words: Polycystic Ovary Syndrome (PCOS), insulin resistance, hyperandrogenism, Rotterdam criteria, metformin, lifestyle interventions

INTRODUCTION

Polycystic Ovary Syndrome (PCOS), also known as the Stein-Leventhal syndrome, is a multifaceted endocrine and metabolic disorder, often presenting during puberty. It is characterized by a range of clinical and biochemical abnormalities, including hormonal imbalances that lead to antral follicle formation, irregular menstruation, and infertility. PCOS is further linked to insulin resistance, cardiovascular disease, abdominal obesity, psychological conditions, and an elevated risk of certain cancers. (1)

Epidemiology

Polycystic ovary syndrome affects **7%** to **15%** of women of reproductive age. Accurate prevalence data is difficult to obtain due to inconsistent definitions of the syndrome and its subphenotypes, as well as variations among study populations and recruitment methods. (2)

Diagnostic Criteria

Over recent decades, efforts have been made to standardize the diagnosis of polycystic ovary syndrome. European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) introduced the Rotterdam criteria, which mandate the presence of at least two of the following: oligo-anovulation, clinical/biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasonography. (3) Despite these criteria, significant variability persists in reported prevalence

across epidemiological studies, largely due to differences in study populations, sampling methods, protocols, and inconsistent definitions of PCOS phenotypes.(4)

The Rotterdam criteria define four PCOS phenotypes: Type A (Classic PCOS) includes hyperandrogenism (HA), ovulatory dysfunction (OD), and polycystic ovary morphology (PCOM); Type B includes HA and OD; Type C includes HA and PCOM; and Type D includes OD and PCOM. With advancements in three-dimensional ovarian imaging and standardized anti-Müllerian hormone (AMH) assays, Type B may eventually be reclassified as Type A due to improved follicle population assessment.(5)(6)

Etiology

Etiology of PCOS remains uncertain, and effective treatment guidelines are lacking. A dysfunction in ovarian theca cells is believed to lead to excessive androgen production and associated clinical manifestations. A key feature of PCOS is the increased ratio of luteinizing hormone (LH) to follicle-stimulating hormone (FSH). The relationship between causative factors and effects in PCOS pathogenesis is often unclear. Furthermore, obesity tends to worsen menstrual irregularities and hyperandrogenism, while weight loss may improve these symptoms. Insulin resistance is a major concern women with PCOS.(7)

In women, androgens are primarily produced by the adrenal glands and ovaries during reproductive years. Approximately 33% of circulating testosterone originates from ovarian theca cells, while the remainder is derived from androstenedione (A4), produced by both glands and converted to testosterone in peripheral tissues. Testosterone is further metabolized to dihydrotestosterone (DHT) via 5-alpha reductase in ovarian granulosa cells and peripheral tissues like the skin.

The ovaries and adrenal glands also secrete dehydroepiandrosterone (DHEA) and A4, while dehydroepiandrosterone sulfate (DHEA-S) is exclusively produced in the adrenal zona reticularis under ACTH regulation. In contrast, ovarian androgen production is controlled by luteinizing hormone (LH). Except for DHEA-S, circulating androgen levels fluctuate with the menstrual cycle phase. (8)

TREATMENT

Non-pharmacological measures

Several studies(9) have shown that a 5 to 10% weight loss in overweight and obese women may be sufficient to restore regular ovulation. A 2013 study(10) found that women with polycystic ovary syndrome had a higher mean BMI compared to those without the condition (29.3 ± 7.5 vs. 25.6 ± 5.8 kg/m², $P < 0.001$). Although women with PCOS reported better dietary quality—higher micronutrient intake and lower saturated fat and glycemic index—their total energy intake was also elevated, along with increased sedentary behavior, while total physical activity levels were similar to non-PCOS women. Factors such as PCOS status, increased energy intake, higher glycemic index, and lower physical activity, along with age, smoking, alcohol consumption, occupation, education, and country of birth, were independently associated with BMI. Various elements, including poor dietary habits, lifestyle choices, inadequate care, late diagnosis, and lack of awareness, contribute to the prevalence of PCOS. A balanced diet consisting of 40% carbohydrates, 30% fats, and 30% proteins, coupled with regular physical activity, is recommended to alleviate severe PCOS symptoms and enhance metabolic health.(11). A meta-analysis indicates that obese women with diagnosed PCOS with bariatric surgery presented a decrease in testosterone levels. (12)

Pharmacological measures

The management of PCOS primarily targets three key areas:

- 1. reducing hyperandrogenism,**
- 2. improving metabolic parameters,**
- 3. normalizing menstrual cycles.**

These objectives are interdependent and closely interconnected, with improvements in one domain often influencing outcomes in the others. Medications used in PCOS management frequently target one or more of these key areas, addressing specific symptoms or exerting

broader effects on the syndrome as a whole. Therefore, the approach to treatment is tailored to the clinical symptoms and phenotypes outlined in the introduction, ensuring a more personalized and effective management strategy.

This represents a simplified approach, as other additional factors, such as infertility, also play a critical role in PCOS management. However, infertility is closely linked to the key areas mentioned above, and while addressing it is essential, the treatment of infertility is beyond the scope of this paper.

Furthermore, emerging research suggests that beyond pharmacological interventions, supplements, including herbal remedies, may positively impact symptoms and overall well-being. However, these studies remain controversial, and the scientific community has not yet reached a consensus on their efficacy or safety. As such, these complementary approaches are also not addressed in this paper. (13) (14)

Additionally, the medications discussed below represent only some of the available options, highlighting the diverse and individualized approaches to managing this complex syndrome.

- **Combined oral contraceptive pills**

Combined oral contraceptive pills (COCPs), containing both estrogen and progestogen, are among the most common treatments for PCOS. By suppressing the hypothalamus–pituitary axis, COCPs regulate menstrual cycles and act as hormone replacement therapy. They are particularly suitable for women with PCOS not seeking pregnancy. A systematic review confirmed their effectiveness in improving menstrual regularity and reducing hirsutism, with COCPs containing cyproterone acetate showing greater efficacy in managing hirsutism compared to standard formulations.(15)(16)

- **Myo-inositol**

Myo-inositol, a stereoisomer of a C6 sugar alcohol in the inositol family, serves as a precursor to inositol triphosphate, an intracellular second messenger regulating hormones like thyroid-stimulating hormone, follicle-stimulating hormone (FSH), and

insulin. It plays a crucial role in the follicular microenvironment, supporting oocyte development, maturation, and FSH signaling in PCOS treatment. Myo-inositol effectively regulates plasma insulin levels, the homeostasis model assessment (HOMA) index, and hormones such as LH, LH/FSH ratio, testosterone, and prolactin.(17) (18)

- **Spironolactone**

Spironolactone, an androgen receptor antagonist, is significant in treating hyperandrogenism. When prescribed for acne in women, it may reduce the reliance on antibiotics and potentially isotretinoin. Additionally, it may benefit conditions such as hidradenitis suppurativa and female androgenetic alopecia. As a monotherapy, spironolactone is as effective as cyproterone acetate combined with estradiol for the long-term management of idiopathic hirsutism. In patients with PCOS, spironolactone effectively reduces hirsutism; however, to address the hormonal or metabolic aspects of PCOS, it may need to be combined with either an antigonadotrophic agent or a drug that enhances peripheral insulin sensitivity. (19) (20)

METFORMIN

N,N'-Dimethylbiguanide, commonly known as Metformin, is an antidiabetic medication that enhances glucose utilization in insulin-sensitive tissues. Given that polycystic ovary syndrome (PCOS) and diabetes share several altered parameters, including abnormal glucose-to-insulin ratios, disrupted lipid metabolism, and insulin resistance, the use of Metformin has gained significant acceptance and is increasingly widespread in the management of PCOS.

Metformin primarily exerts its effects through three key mechanisms. First, it enhances insulin sensitivity, allowing for improved glucose uptake by the body's cells. Second, it inhibits gluconeogenesis in the liver, reducing glucose production and helping to maintain normal blood sugar levels. Third, metformin influences lipid metabolism, which can lead to lower levels of cholesterol and triglycerides(21)

Insuline sensitivity

Metformin is the most commonly prescribed medication for the management of type 2 diabetes (T2D) and is recognized as an "essential medicine" by the World Health Organization. (22) Numerous studies in both animal models and humans have identified impaired GLUT4-mediated glucose uptake as a key mechanism underlying insulin resistance (IR). While Metformin is primarily known for its ability to lower plasma glucose levels, research into its additional properties and effects is ongoing. In terms of glucose homeostasis, Metformin primarily functions by enhancing insulin-mediated suppression of hepatic glucose production and improving insulin-stimulated glucose uptake in peripheral tissues. (23) (24)

Experimental studies have demonstrated that the improvements in insulin sensitivity associated with Metformin may involve several mechanisms. These include increased insulin receptor tyrosine kinase activity, enhanced glycogen synthesis, and, at the most downstream level, increased recruitment and activity of GLUT4.(25)

Findings emerged from studies examining GLUT4 expression in the endometria of patients with polycystic ovary syndrome (PCOS). Researchers observed that GLUT4 mRNA and protein levels were significantly higher in the endometria of PCOS patients who had been on Metformin for at least three months compared to those not receiving Metformin, with levels reaching similar values to those found in the control group.(26)

Inhibition of gluconeogenesis

Hepatic glucose production (HGP) constitutes approximately 90% of endogenous glucose production and is essential for systemic glucose homeostasis. (27)The regulation of HGP involves the suppression of both hepatic glycogenolysis and gluconeogenesis. The liver plays a critical role in maintaining normal glucose levels; it produces glucose during fasting periods and stores it postprandially. However, these hepatic processes can become dysregulated, leading to impaired glucose homeostasis.(28)

One of the most thoroughly investigated mechanisms of metformin is its activation of the signaling kinase AMP-activated protein kinase (AMPK). Recent studies indicate that metformin activates AMPK by decreasing hepatic energy charge, which increases the ratios of

[AMP]:[ADP] and/or [ADP]:[ATP].(29) Additionally, metformin may activate AMPK through the upstream kinase LKB1, resulting in the downregulation of gluconeogenic gene transcription. Metformin has a milder effect compared to other related guanidine and biguanide compounds, such as galegine and phenformin. However, phenformin was removed from clinical use due to its adverse effects, particularly the heightened risk of lactic acidosis. (30)

Metformin, similar to other biguanide-class medications, elevates plasma lactate levels in a concentration-dependent manner by inhibiting mitochondrial respiration predominantly in the liver. Metformin-associated lactic acidosis (MALA) generally arises when high plasma metformin concentrations—often observed in patients with renal impairment—coexist with additional factors that hinder lactate production or clearance, such as cirrhosis, sepsis, or hypoperfusion.(31)

The impact of metformin on plasma lactate levels in bariatric surgery patients remains unexplored; however, these individuals may be at a heightened risk for metformin-associated lactic acidosis (MALA) due to enhanced absorption and bioavailability of the drug.

Many individuals with diabetes continue to take metformin even when they have conditions that increase their risk for lactic acidosis. Some estimates indicate that approximately 25% of patients prescribed metformin have one or more contraindications to its use.(32)

Renal dialysis is recommended for the treatment of metformin-associated lactic acidosis (MALA) to facilitate the removal of metformin and correct metabolic acidosis. This approach underscores the relationship between elevated plasma metformin concentrations and increased plasma lactate levels.(33) (34)

CONCLUSION

Polycystic Ovary Syndrome is a complex endocrine and metabolic disorder affecting 7% to 15% of women of reproductive age. Characterized by hormonal imbalances, including hyperandrogenism, irregular menstruation, and insulin resistance, PCOS is associated with a variety of health issues such as infertility, cardiovascular disease, and an increased risk of

certain cancers. The diagnosis of PCOS is guided by the Rotterdam criteria, which require the presence of at least two of the following: oligo-anovulation, hyperandrogenism, and polycystic ovarian morphology.

Treatment strategies for PCOS focus on three key areas: reducing hyperandrogenism, improving metabolic health, and normalizing menstrual cycles. Both pharmacological and non-pharmacological measures are employed, with lifestyle modifications such as weight loss and a balanced diet being critical. Among pharmacological options, combined oral contraceptives, spironolactone, and myo-inositol are commonly used. Metformin, an antidiabetic medication, is increasingly recognized for its role in managing PCOS due to its effects on insulin sensitivity, gluconeogenesis inhibition, and lipid metabolism.

Metformin enhances glucose utilization in insulin-sensitive tissues and helps regulate metabolic parameters in women with PCOS, making it a valuable treatment option. However, the management of PCOS should be individualized, taking into account the specific symptoms and phenotypes of each patient. While metformin is a cornerstone of therapy, other therapeutic strategies and complementary approaches, such as herbal supplements, are also emerging, although their efficacy requires further investigation. Overall, a multifaceted and personalized approach to treatment is essential for effectively managing the complexities of PCOS.

Disclosure: Authors do not report any disclosures.

Authors' contribution:

Conceptualization: Marta Jajczak, Martyna Kaźmierczak;

Methodology: Mateusz Litwin, Jakub Parys

Investigation: Jakub Parys, Stanisław Jesionek

Sources: Maciej Mossakowski, Aleksandra Witek

Formal analysis: Agnieszka Mikosińska, Marta Jajczak

Visualization: Jakub Parys, Agnieszka Mikosińska

Validation: Maciej Mossakowski, Stanisław Jesionek

Supervision: Patrycja Kałuziak,

Writing - original draft: Martyna Kaźmierczak

Writing - review and editing: Aleksandra Witek, Mateusz Litwin

Project administration: Patrycja Kałuziak,

All authors have read and agreed with the published version of the manuscript.

Funding Statement: Study did not receive special funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Not applicable.

Conflict of Interest: The authors of the paper declare no conflict of interest

References

1. Siddiqui S, Mateen S, Ahmad R, Moin S. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS). *J Assist Reprod Genet.* listopad 2022;39(11):2439–73.
2. Collée J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. *Gynecol Endocrinol.* 3 październik 2021;37(10):869–74.
3. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod.* 1 styczeń 2004;19(1):41–7.

4. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod.* grudzień 2016;31(12):2841–55.
5. Stener-Victorin E, Padmanabhan V, Walters KA, Campbell RE, Benrick A, Giacobini P, i in. *Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.* *Endocr Rev.* 1 sierpień 2020;41(4):bnaa010.
6. Yuwen T, Yang Z, Cai G, Feng G, Liu Q, Fu H. Association between serum AMH levels and IVF/ICSI outcomes in patients with polycystic ovary syndrome: a systematic review and meta-analysis. *Reprod Biol Endocrinol.* 23 październik 2023;21(1):95.
7. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What's new? *Adv Clin Exp Med.* 27 kwiecień 2017;26(2):359–67.
8. Sharma A, Welt CK. Practical Approach to Hyperandrogenism in Women. *Med Clin North Am.* listopad 2021;105(6):1099–116.
9. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, i in. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. *Clin Endocrinol (Oxf).* styczeń 1992;36(1):105–11.
10. Moran LJ, Ranasinha S, Zoungas S, McNaughton SA, Brown WJ, Teede HJ. The contribution of diet, physical activity and sedentary behaviour to body mass index in women with and without polycystic ovary syndrome. *Hum Reprod.* sierpień 2013;28(8):2276–83.
11. Shahid R, Iqbal-Ul-Haq, Mahnoor, Awan KA, Iqbal MJ, Munir H, i in. Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). *J Food Biochem [Internet].* lipiec 2022 [cytowane 17 grudzień 2024];46(7). Dostępne na: <https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14117>
12. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JJ. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. *Hum Reprod Update.* 1 lipiec 2017;23(4):390–408.

13. Han Y, Hou Y, Han Q, Yuan X, Chen L. Dietary supplements in polycystic ovary syndrome—current evidence. *Front Endocrinol.* 27 wrzesień 2024;15:1456571.
14. Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. *BMC Complement Altern Med.* grudzień 2017;17(1):500.
15. Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, i in. Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review. *Clin Endocrinol (Oxf).* lipiec 2023;99(1):79–91.
16. Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, i in. Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. *J Clin Endocrinol Metab.* 18 styczeń 2024;109(2):e817–36.
17. Pkhaladze L, Russo M, Unfer V, Nordio M, Basciani S, Khomasuridze A. Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives. *Eur Rev Med Pharmacol Sci.* grudzień 2021;25(23):7476–85.
18. Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. *Endocr Connect.* listopad 2017;6(8):647–58.
19. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. *Clin Endocrinol (Oxf).* 19 maj 2000;52(5):587–94.
20. Zeng H, Zhang Y, Huang S, Wu J, Ren W, Zhou L, i in. Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. *Front Endocrinol.* 10 sierpień 2023;14:1223768.
21. Motta A. Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome. *Curr Pharm Des.* 1 wrzesień 2009;15(26):3074–7.
22. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Medical Care in Diabetes—2020.* *Diabetes Care.* 1 styczeń 2020;43(Supplement_1):S98–110.

23. LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. *Endocr Rev.* 28 styczeń 2021;42(1):77–96.
24. Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. *Int J Mol Sci.* 23 styczeń 2022;23(3):1264.
25. Giannarelli R, Aragona M, Coppelli A, Del Prato S. Reducing insulin resistance with metformin: the evidence today. *Diabetes Metab.* wrzesień 2003;29(4):6S28–35.
26. Carvajal R, Rosas C, Kohan K, Gabler F, Vantman D, Romero C, i in. Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients. *Hum Reprod.* 1 sierpień 2013;28(8):2235–44.
27. Moore MC, Coate KC, Winnick JJ, An Z, Cherrington AD. Regulation of Hepatic Glucose Uptake and Storage In Vivo. *Adv Nutr.* maj 2012;3(3):286–94.
28. Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. *Nat Rev Endocrinol.* październik 2017;13(10):572–87.
29. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, i in. Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest.* 15 październik 2001;108(8):1167–74.
30. Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. *Nat Rev Endocrinol.* marzec 2014;10(3):143–56.
31. DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: Current perspectives on causes and risk. *Metabolism.* luty 2016;65(2):20–9.
32. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD, for the DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with Type 2 diabetes—a population-based study of adherence to prescribing guidelines. *Diabet Med.* czerwiec 2001;18(6):483–8.

33. Arroyo AM, Walroth TA, Mowry JB, Kao LW. The MALAdy of Metformin Poisoning: Is CVVH the Cure? *Am J Ther.* styczeń 2010;17(1):96–100.
34. Keller G, Cour M, Hernu R, Illinger J, Robert D, Argaud L. Management of Metformin-Associated Lactic Acidosis by Continuous Renal Replacement Therapy. Gold JA, redaktor. *PLoS ONE.* 11 sierpień 2011;6(8):e23200.